[pending] METOPROLOL SUCCINATE (METOPROLOL SUCCINATE)
Pending LLM rewrite. Source: FDA_DRUG D-0357-2026.
- Product
- METOPROLOL SUCCINATE — METOPROLOL SUCCINATE (METOPROLOL SUCCINATE)
- Category
- Drug
- Distribution
- Distributed nationwide
Category
FDA recalls of prescription and over-the-counter drugs.
FDA drug recalls cover prescription medicines, over-the-counter products, biologic and gene therapies, and active pharmaceutical ingredients (the raw drug substances that manufacturers compound into finished products). Recall classifications follow the same Class I / II / III system as food, and most published recalls are Class II — the product is unlikely to cause permanent harm but doesn't meet specification.
The most common reasons for a drug recall are out-of-specification potency or dissolution (the active ingredient is present in too high or too low a dose), microbial contamination, particulate matter in injectables, mix-ups during packaging where bottles end up with the wrong tablets, and nitrosamine impurities in certain drug classes. Many drug recalls are at the lot level — the manufacturer's whole product line is still safe to use, but specific production lots are pulled.
If a recall affects your medication: don't stop taking it on your own. Call your prescriber or pharmacist before doing anything. Stopping a prescribed drug abruptly can be more dangerous than the issue prompting the recall. Most drug-recall remedies route through the dispensing pharmacy, who'll either swap your supply for an unaffected lot or coordinate a refund with the manufacturer.
Pending LLM rewrite. Source: FDA_DRUG D-0357-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0359-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0372-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0350-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0344-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0346-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0347-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0343-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0348-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0345-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0341-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0339-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0352-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0349-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0351-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0303-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0321-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0328-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0325-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0306-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0312-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0326-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0329-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0317-2026.
Pending LLM rewrite. Source: FDA_DRUG D-0338-2026.
Looking for a different category? Browse all recalls.